Albemarle Corp. Stock Slides 5.9%, Underperforms Peers
Dow Jones2026/08/25 20:33This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Albemarle Corp. shed 5.9% to $133.18 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.3% to 7,677.28 and the Dow Jones Industrial Average rising 0.3% to 53,577.40.
This was the stock's second consecutive day of losses.
Albemarle Corp. closed 39.7% below its 52-week high of $221.00, which the company achieved on May 7th.
The stock underperformed when compared to some of its peers, as Avantor Inc. rose 1.1% to $14.42, Celanese Corp. fell 1.6% to $44.52, and Eastman Chemical Co. fell 0.92% to $72.02.
Trading volume totaled 2.3 million, compared to the 50-day average of 2.4 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 25, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A key leap toward the internationalization of the Korean won: The Bank of Korea launches a trial run of its 24/7 international settlement system, with full deployment set for January next year.
The Bank of Korea officially launched the trial operation of the "BOK Won International Payment Network" on Monday local time.
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Crypto prices
More
